These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 21494127)
1. Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease. Suzuki T; Nozawa T; Fujii N; Sobajima M; Ohori T; Shida T; Matsuki A; Kameyama T; Inoue H Coron Artery Dis; 2011 Aug; 22(5):352-8. PubMed ID: 21494127 [TBL] [Abstract][Full Text] [Related]
2. Plaque regression in one artery is not necessarily associated with parallel changes in other vascular beds. Suzuki T; Nozawa T; Fujii N; Sobajima M; Ohori T; Shida T; Matsuki A; Kameyama T; Inoue H Heart Vessels; 2011 May; 26(3):242-51. PubMed ID: 20953613 [TBL] [Abstract][Full Text] [Related]
3. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430 [TBL] [Abstract][Full Text] [Related]
4. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis. Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609 [TBL] [Abstract][Full Text] [Related]
5. C-reactive protein levels and outcomes after statin therapy. Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E; N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109 [TBL] [Abstract][Full Text] [Related]
6. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151 [TBL] [Abstract][Full Text] [Related]
7. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial. Shukla A; Sharma MK; Jain A; Goel PK Indian Heart J; 2005; 57(6):675-80. PubMed ID: 16521637 [TBL] [Abstract][Full Text] [Related]
8. Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia. Ercan E; Tengiz I; Altuglu I; Sekuri C; Aliyev E; Ercan HE; Akin M Kardiol Pol; 2004 May; 60(5):454-8. PubMed ID: 15247960 [TBL] [Abstract][Full Text] [Related]
9. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. Sang ZC; Wang F; Zhou Q; Li YH; Li YG; Wang HP; Chen SY Chin Med J (Engl); 2009 Jul; 122(14):1615-20. PubMed ID: 19719960 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. Azar M; Valentin E; Badaoui G; Kassab R; Sarkis A; Azar RR Am J Cardiol; 2011 Jun; 107(11):1571-4. PubMed ID: 21439529 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326 [TBL] [Abstract][Full Text] [Related]
12. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A; J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114 [TBL] [Abstract][Full Text] [Related]
13. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease. Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882 [TBL] [Abstract][Full Text] [Related]
14. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study). Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M; Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122 [TBL] [Abstract][Full Text] [Related]
15. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Takahashi Y; Satoh M; Minami Y; Tabuchi T; Itoh T; Nakamura M Clin Sci (Lond); 2010 Jul; 119(9):395-405. PubMed ID: 20524934 [TBL] [Abstract][Full Text] [Related]
16. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. Komukai K; Kubo T; Kitabata H; Matsuo Y; Ozaki Y; Takarada S; Okumoto Y; Shiono Y; Orii M; Shimamura K; Ueno S; Yamano T; Tanimoto T; Ino Y; Yamaguchi T; Kumiko H; Tanaka A; Imanishi T; Akagi H; Akasaka T J Am Coll Cardiol; 2014 Dec; 64(21):2207-17. PubMed ID: 25456755 [TBL] [Abstract][Full Text] [Related]
17. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy. Puri R; Nissen SE; Shao M; Uno K; Kataoka Y; Kapadia SR; Tuzcu EM; Nicholls SJ Am J Cardiol; 2014 Nov; 114(10):1465-72. PubMed ID: 25282317 [TBL] [Abstract][Full Text] [Related]
18. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465 [TBL] [Abstract][Full Text] [Related]
19. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Ostad MA; Eggeling S; Tschentscher P; Schwedhelm E; Böger R; Wenzel P; Meinertz T; Munzel T; Warnholtz A Atherosclerosis; 2009 Jul; 205(1):227-32. PubMed ID: 19150064 [TBL] [Abstract][Full Text] [Related]
20. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S; J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]